ES2083074T3 - Dispositivo de liberacion controlada. - Google Patents

Dispositivo de liberacion controlada.

Info

Publication number
ES2083074T3
ES2083074T3 ES92203447T ES92203447T ES2083074T3 ES 2083074 T3 ES2083074 T3 ES 2083074T3 ES 92203447 T ES92203447 T ES 92203447T ES 92203447 T ES92203447 T ES 92203447T ES 2083074 T3 ES2083074 T3 ES 2083074T3
Authority
ES
Spain
Prior art keywords
active substance
exposed
dissolution
fluid
nucleus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92203447T
Other languages
English (en)
Inventor
Sham Kumar Chopra
Avinash Kumar Nangia
David Lee
Thomas Patrick Molloy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Inc
Original Assignee
Glaxo Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919124106A external-priority patent/GB9124106D0/en
Priority claimed from GB919124108A external-priority patent/GB9124108D0/en
Priority claimed from GB929205463A external-priority patent/GB9205463D0/en
Application filed by Glaxo Canada Inc filed Critical Glaxo Canada Inc
Application granted granted Critical
Publication of ES2083074T3 publication Critical patent/ES2083074T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Molding Of Porous Articles (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seal Device For Vehicle (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Container, Conveyance, Adherence, Positioning, Of Wafer (AREA)

Abstract

EL INVENTO MUESTRA UN DISPOSITIVO PARA LA LIBERACION DE AL MENOS UNA SUSTANCIA ACTIVA (POR EJEMPLO RANITIDINA) EN UN MEDIO DE FLUIDO POR DISOLUCION QUE COMPRENDE UNA COBERTURA, QUE ES IMPERMEABLE A LA SUSTANCIA ACTIVA Y EL FLUIDO, CON AL MENOS UNA ABERTURA EN SU INTERIOR Y QUE DEFINE UNA CAVIDAD LLENA DE UN NUCLEO QUE COMPRENDE LA SUSTANCIA ACTIVA Y EN DONDE: A) AL EXPONER EL DISPOSITIVO AL MEDIO DE FLUIDO, SE EXPONE UNA SUPERFICIE DEL NUCLEO Y LA DISOLUCION DE LA SUPERFICIE POR EL MEDIO DE FLUIDO PROVOCA UN CAMBIO AL MENOS EN UNA DIMENSION DEL AREA DE LA SUPERFICIE, MIENTRAS QUE EL AREA SUPERFICIAL DE LA SUPERFICIE EXPUESTA PERMANECE BASICAMENTE CONSTANTE EN AL MENOS UN 50% DEL TIEMPO DE DISOLUCION TOTAL EN EL NUCLEO; O B) LA SUSTANCIA ACTIVA SE EXPONE EN UNA MATRIZ DE EXCIPIENTE INSOLUBLE INERTE, ESTANDO EL DISPOSITIVO AXIALMENTE SIMETRICO, CON SU ABERTURA COLOCADA PERIFERICAMENTE DE MODO QUE LA SUPERFICIE DE LIBERACION DEL NUCLEO QUE ESTA EXPUESTO A TRAVES DE LA ABERTURA SEA BASICAMENTECILINDRICA O PARCIALMENTE CILINDRICA EN FORMA, POR LO QUE PERMITE BASICAMENTE LA LIBERACION CONSTANTE DE LA SUSTANCIA ACTIVA AL MENOS DURANTE PARTE DEL TIEMPO DE DISOLUCION; ASI COMO PROCESOS PARA SU PREPARACION.
ES92203447T 1991-11-13 1992-11-10 Dispositivo de liberacion controlada. Expired - Lifetime ES2083074T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919124106A GB9124106D0 (en) 1991-11-13 1991-11-13 Device
GB919124108A GB9124108D0 (en) 1991-11-13 1991-11-13 Device
GB929205463A GB9205463D0 (en) 1992-03-12 1992-03-12 Device

Publications (1)

Publication Number Publication Date
ES2083074T3 true ES2083074T3 (es) 1996-04-01

Family

ID=27265924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92203447T Expired - Lifetime ES2083074T3 (es) 1991-11-13 1992-11-10 Dispositivo de liberacion controlada.

Country Status (15)

Country Link
US (1) US5342627A (es)
EP (1) EP0542364B1 (es)
JP (2) JP3768247B2 (es)
AT (1) ATE133331T1 (es)
AU (1) AU658942B2 (es)
CA (1) CA2082740C (es)
CZ (1) CZ337392A3 (es)
DE (1) DE69207863T2 (es)
DK (1) DK0542364T3 (es)
ES (1) ES2083074T3 (es)
GR (1) GR3019431T3 (es)
IL (1) IL103723A0 (es)
NO (1) NO924372L (es)
NZ (1) NZ245100A (es)
TW (1) TW262387B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5398850A (en) 1993-08-06 1995-03-21 River Medical, Inc. Gas delivery apparatus for infusion
DE4341442C2 (de) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
DE4431653C2 (de) 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US5700245A (en) 1995-07-13 1997-12-23 Winfield Medical Apparatus for the generation of gas pressure for controlled fluid delivery
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US6110500A (en) * 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
EP1095650A1 (en) * 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2002047693A2 (en) * 2000-12-14 2002-06-20 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products comprising a stabilizing agent in non-crystalline form
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
EP1446100B1 (en) * 2001-11-14 2011-05-04 Durect Corporation Injectable depot compositions and uses thereof
NZ533436A (en) 2001-11-14 2007-10-26 Alza Corp Catheter injectable depot compositons and uses thereof
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
JP4744142B2 (ja) * 2002-07-29 2011-08-10 グラクソ グループ リミテッド ラモトリギンを含む徐放性処方
KR20050038008A (ko) * 2002-07-31 2005-04-25 알자 코포레이션 주사용 저장형 조성물 및 이의 용도
DK1539101T3 (da) * 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2007073702A2 (es) 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20110142905A1 (en) * 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
WO2010096820A1 (en) * 2009-02-23 2010-08-26 Eurand, Inc. Controlled release compositions comprising anti-cholinergic drugs
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
AU2011342893A1 (en) * 2010-12-13 2013-05-02 Purdue Pharma L.P. Controlled release dosage forms
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
US9988669B2 (en) 2014-04-14 2018-06-05 Abbott Molecular Inc. Medium used for blood sample collection and transport
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US480076A (en) * 1892-08-02 Thomas p
US3113076A (en) * 1956-07-03 1963-12-03 Henry R Jacobs Medicinal tablets
GB1022171A (en) * 1961-06-15 1966-03-09 Wellcome Found Prolonged release oral pharmaceutical tablets and their manufacture
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance

Also Published As

Publication number Publication date
AU658942B2 (en) 1995-05-04
JP4166716B2 (ja) 2008-10-15
EP0542364B1 (en) 1996-01-24
EP0542364A1 (en) 1993-05-19
DE69207863D1 (de) 1996-03-07
DE69207863T2 (de) 1996-06-05
GR3019431T3 (en) 1996-06-30
JP2004189754A (ja) 2004-07-08
ATE133331T1 (de) 1996-02-15
US5342627A (en) 1994-08-30
CA2082740C (en) 2003-10-14
TW262387B (es) 1995-11-11
JPH05262640A (ja) 1993-10-12
DK0542364T3 (da) 1996-03-11
IL103723A0 (en) 1993-04-04
JP3768247B2 (ja) 2006-04-19
CA2082740A1 (en) 1993-05-14
NZ245100A (en) 1995-06-27
CZ337392A3 (en) 1993-10-13
NO924372D0 (no) 1992-11-12
NO924372L (no) 1993-05-14
AU2827292A (en) 1993-05-20

Similar Documents

Publication Publication Date Title
ES2083074T3 (es) Dispositivo de liberacion controlada.
AU4778485A (en) An additive composition for increasing the conductivity of anorganic polymer, an active hydrogen-containing composition containing the additive composition, & an organic polymer
ES2010648A4 (es) Formulaciones farmaceuticas de sustancias labiles frente a los acidospara uso oral.
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
SV2002000586A (es) Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b
ES2101710T3 (es) Procedimiento fotolitografico.
ES2523649T3 (es) Láminas para elementos estructurales electroquímicos y procedimiento para su producción
PE20001326A1 (es) Composicion farmaceutica que comprende cefuroxima-axetil, polimero y/o adsorbente
EP0243834A3 (en) Substituted oxime ethers; their use as bioregulators for lowering the endogene ethylene level in plants
EP1041399A3 (en) Radiation exposure dose-history indicator
ES2058050T1 (es) Metodo y equipo para el ensayo de citotoxicidad de celulas tumorales.
ES2133936T3 (es) Procedimiento para la preparacion de 1,2-benzisotiazolin-3-onas.
EP0331745A4 (en) Ferrocene derivatives, surfactants containing same, and process for producing thin organic film
ES514767A0 (es) Procedimiento para preparar derivados de aminoglicosidos.
ES492846A0 (es) Procedimiento para el cultivo superficial de celulas que contienen nucleos.
DK6886D0 (da) Middel til at haeve ph-vaerdien af tandplak og fremgangsmaade til fremstilling af midlet
JPS5217897A (en) Composition for detection of occult blood
DE3268605D1 (en) 3,7a-diazacyclohepta(j,k)fluorene derivatives, their preparation and therapeutical use
DK455487D0 (da) 13alfa-alkylgonan-delta9(11)-5,10-epoxider og fremgangsmaade til fremstilling deraf
JPS51124673A (en) An anode for electrolytic water manufacturing apparatus for medical us e
ES2032838T3 (es) Un procedimiento para preparar derivados tetrahidropirido (1,2-a)indol.
ES2152825B1 (es) Metodo general de obtencion de esteres del acido poli (-glutamico) mediante transesterificacion.
MX161252A (es) Procedimiento microbiologico para la obtencion de una mezcla de derivados de dodecahidro-3a.6.6.91a-trtrametilnafto(2,1-b)furano
IT8719371A0 (it) Derivati del 9,10-diidro fenantrene e procedimento per la loro preparazione.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 542364

Country of ref document: ES